Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis. J Comp Eff Res 2018 11;7(11):1053-1062

Date

10/26/2018

Pubmed ID

30354284

DOI

10.2217/cer-2018-0062

Scopus ID

2-s2.0-85056393482   1 Citation

Abstract

AIMS: Examine mortality and healthcare costs in Medicare beneficiaries with newly diagnosed immunoglobulin light chain (AL) amyloidosis.

PATIENTS & METHODS: Cases were identified in 2012-2015 Medicare 5% data with ≥1 inpatient/≥2 outpatient claims consistent with AL amyloidosis and ≥1 AL-specific treatment. Cases were matched 3:1 with disease-free controls. Descriptive statistics were reported.

RESULTS: A total of 249 (33.3%) cases were matched to 747 (66.7%) controls. A total of 19.7% of cases died within 1 year of follow-up versus 5.5% of controls; 30.6 versus 11.8% died within 2 years (p < 0.001). Mean (SD) costs in 1-year of follow-up were significantly higher among cases versus controls ($71,040 [65,766] vs $13,722 [27,493]; p < 0.001).

CONCLUSION: Mortality was nearly four-times higher, and costs nearly five-times higher in beneficiaries with AL amyloidosis versus controls.

Author List

Quock TP, Chang E, Munday JS, D'Souza A, Gokhale S, Yan T

Author

Anita D'Souza MD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Aged
Aged, 80 and over
Case-Control Studies
Female
Health Care Costs
Humans
Immunoglobulin Light-chain Amyloidosis
Inpatients
Male
Medicare
Retrospective Studies
United States
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a